Showing 5 ideas for tag "autoimmune"

Goal 3: Advance Translational Research

Identification of autoantigens that elicit pathogenic immune responses in cardiovascular diseases

Pathogenic immune responses participate in the pathogenesis of many cardiovascular diseases. However, the autoantigens and foreign antigens that elicit the pathogenic immune responses have been poorly identified. Currently, the regulatory mechanisms on immune responses associated with diseases got some attentions. But, without detailed characterizations of this wide spectrum of autoantigens and foreign antigens in patients... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Critical Challenge (CC)

Feasibility and challenges of addressing this CQ or CC
  1. use peptide/protein based microarray to antibody autoimmune responses associated with each major cardiovascular diseases;
  2. use MHC tetra-mers or similar techniques to characterize T cell autoimmune responses associated with each major cardiovascular diseases;
  3. determine autoantigen repertoire changes in patients' responses to current therapies, especially therapies with immune modulating effects;
  4. develop autoantigens-based immune therapies for clinical trials

Name of idea submitter and other team members who worked on this idea Professor Xiaofeng Yang, MD, PhD, Professor Hong Wang, MD, PhD, Professor Klaus Ley, MD

Voting

26 net votes
28 up votes
2 down votes
Active

Goal 3: Advance Translational Research

Can SYK or BTK inhibition ameliorate autoimmune hemolytic anemia after stem cell transplantation

Experimental mouse models of ITP and AIHA are dependent on FcgR-signaling, which in turn depends on Syk kinase activity for activation of phagocytes. A significant and refractory complication of stem cell transplantation is immune hemolytic anemia. This can be either autoimmune or alloimmune. In either case it is likely that clearance of RBC and RBC progenitors is dependent on extravascular mechanisms involving activation... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Autoimmune hemolytic anemia occurs in about 5% of allogeneic stem cell transplants as a late immunologic complication of immune dysregulation. This occurs either in the setting of chronic GVHD or independently. ABO incompatibility also results in hemolytic anemia which may be complicated by transplant-related mortality or pure red blood cell aplasia. Often ABO incompatible donors are the only option. Targeting of FcgR has not been assessed in this setting and would 1) provide clinical benefit, 2) shed light on the role of FcgR inhibition in a more general way in BMT-related complications.

Feasibility and challenges of addressing this CQ or CC

This interesting question can best be addressed in the context of a network study, since the development of AIHA is uncommon. BMT-CTN would be a superb mechanism to assess feasibility and efficacy and it would be well-positioned to study scientific offshoots of this approach.

Name of idea submitter and other team members who worked on this idea Joseph Antin

Voting

23 net votes
52 up votes
29 down votes
Active

Goal 2: Reduce Human Disease

Relevance of cardiovascular disease associated with autoimmunity research

NIH estimates up to 23.5 million Americans suffer from autoimmune disease (AD) and up to 24 million from heart diseases. As a result, NIH and AHA estimates the annual direct health care costs for AD to be in the range of $100 billion and $200 billion for heart and stroke diseases. Yet this area of research has been neglected and underfunded. The proposition is for NHLBI to partner with other NIH institutes dealing with... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Reduce the impact of autoimmune diseases on the heart and vascular system.

Feasibility and challenges of addressing this CQ or CC

Generate RFAs dedicated to the field of autoimmune associated cardiovascular diseases.

Name of idea submitter and other team members who worked on this idea M. Boutjdir

Voting

11 net votes
15 up votes
4 down votes
Active

Goal 3: Advance Translational Research

Immune-Mediated hematologic disorders

What is the optimal approach to prevent and treat immune mediated hematologic disorders (autoimmune hemolytic anemia, immune thrombocytopenic purpura, etc) and complications of hematologic disease (inhibitors in hemophilia, transfusion-related alloimmunization, etc)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Details on the impact of addressing this CQ or CC

Therapies for these disorders are suboptimal and current treatments are associated with significant side effects. Transfusion is limited by development of alloantibodies..

Feasibility and challenges of addressing this CQ or CC

NHLBI should support clinical trials in this area. Improved understanding of the biology and biomarkers predictive of disease development would aid in defining therapeutic approaches and trials.

Voting

-1 net votes
17 up votes
18 down votes
Active

Goal 3: Advance Translational Research

Improving blood supply by giving a pig a human bone marrow transplant from a universal donor

What do you think of giving a pig a human bone marrow transplant from a universal donor? The pig could produce blood for human use! Although the pig will eventual die of an autoimmune disease its life can be prolonged with all the new autoimmune medicines we have and/or the pig can be engineered to overexpress PDL1 (or a similar autoimmune suppressor). Additionally even if each pint of blood made this way might be... more »

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea John D Marano

Voting

-26 net votes
11 up votes
37 down votes
Active